Strs Ohio Cuts Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Strs Ohio lessened its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 537,850 shares of the company’s stock after selling 28,711 shares during the quarter. Strs Ohio’s holdings in Teva Pharmaceutical Industries were worth $16,200,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of TEVA. Keybank National Association OH grew its stake in shares of Teva Pharmaceutical Industries by 119.6% in the first quarter. Keybank National Association OH now owns 18,394 shares of the company’s stock valued at $554,000 after buying an additional 10,019 shares in the last quarter. IFM Investors Pty Ltd lifted its position in Teva Pharmaceutical Industries by 2.8% during the 1st quarter. IFM Investors Pty Ltd now owns 244,364 shares of the company’s stock worth $7,360,000 after acquiring an additional 6,639 shares in the last quarter. iA Global Asset Management Inc. boosted its holdings in Teva Pharmaceutical Industries by 43.8% in the 1st quarter. iA Global Asset Management Inc. now owns 299,035 shares of the company’s stock worth $9,007,000 after acquiring an additional 91,026 shares during the period. Lansforsakringar Fondforvaltning AB publ boosted its holdings in Teva Pharmaceutical Industries by 0.6% in the 1st quarter. Lansforsakringar Fondforvaltning AB publ now owns 257,909 shares of the company’s stock worth $7,768,000 after acquiring an additional 1,501 shares during the period. Finally, Apollon Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $248,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 21,258 shares of the stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total transaction of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares of the company’s stock, valued at approximately $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the completion of the transaction, the executive vice president owned 55,755 shares of the company’s stock, valued at $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 465,931 shares of company stock worth $16,332,989. Company insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. UBS Group raised their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Bank of America upped their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Finally, Truist Financial raised their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.78.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock opened at $34.55 on Friday. Teva Pharmaceutical Industries Ltd. has a 52 week low of $14.99 and a 52 week high of $37.35. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The stock has a market cap of $39.73 billion, a P/E ratio of 25.98, a price-to-earnings-growth ratio of 4.23 and a beta of 0.86. The stock has a 50 day moving average of $33.96 and a 200-day moving average of $32.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.97 EPS for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.